BILLERICA, Mass., Jan 07, 2010 (BUSINESS WIRE) -- Bruker Corporation (NASDAQ: BRKR) announced today that during the second half of 2009, the Company has already received over 100 additional systems orders from various global stimulus funding budgets. This number excludes 51 mass spectrometers delivered to Japan's National Police Agency in the first half of 2009 under a previous supplementary budget.
All five Bruker operating divisions have received stimulus orders, with most orders for high-end instrumentation, especially for NMR, pre-clinical MRI, mass spectrometry and X-ray systems. Bruker estimates that average selling prices of these stimulus orders were greater than $500,000 per system, with a cumulative amount of stimulus orders already received in the second half of 2009 greater than $70 million. These orders are expected to result in revenues primarily in the year 2010, and into the first half of 2011. The Company expects to receive additional orders from various global stimulus programs, including U.S. ARRA funding, in 2010.
Frank Laukien, President and CEO of Bruker Corporation, commented: "We are delighted that so many top-notch researchers around the world have selected high-performance scientific instruments from Bruker, and we thank our customers for their vote of confidence."
Cautionary Statement
Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, risks and uncertainties relating to adverse changes in conditions in the global economy and volatility in the capital markets, the integration of businesses we have acquired or may acquire in the future, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, realization of anticipated benefits from economic stimulus programs, intellectual property rights, litigation, and exposure to foreign currency fluctuations and other risk factors discussed from time to time in our filings with the Securities and Exchange Commission. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our recent Proxy Statements on Schedule 14A, our annual report on Form 10-K for the year ended December 31, 2008, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.
ABOUT BRUKER CORPORATION
For more information about Bruker Corporation, please visit www.bruker.com.
SOURCE: Bruker Corporation
Bruker Corporation
Stacey Desrochers, +1-978-663-3660, ext. 1115
Director of Investor Relations
stacey.desrochers@bruker.com